In CML, p190Bcr-Abl occurs in a minority of patients associating with distinct hematological features and inferior outcomes, yet the pathogenic role of p190Bcr-Abl and potential targeting therapies are largely uncharacterized. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.